Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more) Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Palatin Technologies Inc PTN

Healthcare Biotechnology
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists... see more

Recent & Breaking News (NYSEAM:PTN)

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017

PR Newswire May 16, 2017

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017

PR Newswire May 11, 2017

Palatin Technologies to Present at The MicroCap Conference on April 4th at 1:00 PM ET in New York City at the Essex House

Accesswire March 31, 2017

Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women

PR Newswire March 20, 2017

Healthcare Stocks on Investors' Radar -- Delcath Systems, Palatin Technologies, AMAG Pharma, and IDEXX Laboratories

PR Newswire March 14, 2017

Palatin Technologies To Present At The 29th Annual ROTH Conference

PR Newswire March 9, 2017

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017

PR Newswire February 9, 2017

Research Reports Initiation on Healthcare Stocks -- Palatin Technologies, AMAG Pharma, IDEXX Labs, and Delcath Systems

PR Newswire February 6, 2017

Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda™

PR Newswire February 3, 2017

Palatin Technologies to Hold Call Following Closing of Licensing Agreement for North American Rights to Rekynda™

PR Newswire January 10, 2017

Mid-Afternoon Market Update: Ariad Pharmaceuticals Surges On Acquisition News; Stage Stores Shares Slide

Benzinga.com  January 9, 2017

AMAG Pharmaceuticals Tanks After Raymond James Downgrade

Benzinga.com  January 9, 2017

AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder

GlobeNewswire January 9, 2017

Palatin Technologies Closes on $16.5 Million Financing

PR Newswire December 7, 2016

Palatin Technologies Announces Pricing of Public Offering of Common Stock and Warrants

PR Newswire December 1, 2016

Palatin Technologies Announces Proposed Public Offering of Common Stock and Warrants

PR Newswire November 30, 2016

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on November 15, 2016

PR Newswire November 15, 2016

Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on November 15, 2016

PR Newswire November 10, 2016

Palatin's Female Arousal Drug Data Impresses, Investors React Positively

Benzinga.com  November 3, 2016

Bremelanotide Meets Co-Primary Endpoints in Palatin's Phase 3 Trials for Hypoactive Sexual Desire Disorder

PR Newswire November 1, 2016